Bionano Genomics (BNGO)
NASDAQ:BNGO
Total Valuation
BioNano Genomics has a market cap or net worth of $12.87M. The enterprise value is $7.73M.
Market Cap$12.87M
Enterprise Value$7.73M
Share Statistics
BioNano Genomics has 11,092,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,092,000
Owned by Insiders1.89%
Owned by Institutions2.23%
Financial Efficiency
BioNano Genomics’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -64.63%.
Return on Equity (ROE)-0.59
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-64.63%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee290.90K
Profits Per Employee-269.34K
Employee Count98
Asset Turnover0.39
Inventory Turnover4.08
Valuation Ratios
The current PE Ratio of BioNano Genomics is ―. BioNano Genomics’s PEG ratio is 0.00334.
PE Ratio―
PS Ratio0.29
PB Ratio0.19
Price to Fair Value0.19
Price to FCF-0.51
Price to Operating Cash Flow-0.39
PEG Ratio0.00334
Income Statement
In the last 12 months, BioNano Genomics had revenue of 28.51M and earned -26.39M in profits. Earnings per share was -4.85.
Revenue28.51M
Gross Profit6.26M
Operating Income-33.34M
Pretax Income-26.33M
Net Income-26.39M
EBITDA-23.61M
Earnings Per Share (EPS)-4.85
Cash Flow
In the last 12 months, operating cash flow was -16.34M and capital expenditures 0.00, giving a free cash flow of -16.34M billion.
Operating Cash Flow-16.34M
Free Cash Flow-16.34M
Free Cash Flow per Share-1.47
Dividends & Yields
BioNano Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-74.34%
50-Day Moving Average1.17
200-Day Moving Average2.08
Relative Strength Index (RSI)48.36
Average Volume (3m)440.75K
Important Dates
BioNano Genomics upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
BioNano Genomics as a current ratio of 1.98, with Debt / Equity ratio of 15.57%
Current Ratio1.98
Quick Ratio1.74
Debt to Market Cap0.83
Net Debt to EBITDA-0.17
Interest Coverage Ratio-111.88
Taxes
In the past 12 months, BioNano Genomics has paid 67.00K in taxes.
Income Tax67.00K
Effective Tax Rate>-0.01
Enterprise Valuation
BioNano Genomics EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.75.
EV to Sales0.43
EV to EBITDA-0.52
EV to Free Cash Flow-0.75
EV to Operating Cash Flow-0.75
Balance Sheet
BioNano Genomics has $13.26M in cash and marketable securities with $6.92M in debt, giving a net cash position of $6.34M billion.
Cash & Marketable Securities$13.26M
Total Debt$6.92M
Net Cash$6.34M
Net Cash Per Share$0.57
Tangible Book Value Per Share$7.36
Margins
Gross margin is 21.95%, with operating margin of -116.95%, and net profit margin of -92.59%.
Gross Margin21.95%
Operating Margin-116.95%
Pretax Margin-92.35%
Net Profit Margin-92.59%
EBITDA Margin-82.81%
EBIT Margin-116.95%
Analyst Forecast
The average price target for BioNano Genomics is $5.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.50
Price Target Upside239.51% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-13.84%
EPS Growth Forecast88.80%